{"id":"haploidentical-bone-marrow-transplant","safety":{"commonSideEffects":[{"rate":null,"effect":"Graft-versus-host disease (GVHD)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Graft failure or delayed engraftment"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Organ toxicity (hepatic, renal, pulmonary)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"In this procedure, bone marrow or mobilized peripheral blood stem cells from a haploidentical donor (typically a parent or child with 50% HLA match) are infused into a conditioned recipient. The donor stem cells engraft and reconstitute the patient's bone marrow, restoring production of blood cells and immune cells. This approach is used to treat hematologic malignancies and severe bone marrow disorders where a fully matched donor is unavailable.","oneSentence":"Haploidentical bone marrow transplant replaces a patient's diseased bone marrow with stem cells from a partially matched donor to restore hematopoietic and immune function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:53.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute leukemia (AML, ALL)"},{"name":"Chronic leukemia (CML, CLL)"},{"name":"Lymphoma"},{"name":"Myelodysplastic syndrome"},{"name":"Severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT07020533","phase":"PHASE1","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-08","conditions":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":46},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":"DOCK8 Deficiency","enrollment":70},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT04579523","phase":"PHASE1","title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT01758042","phase":"NA","title":"Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-11","conditions":"Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)","enrollment":10},{"nctId":"NCT04713046","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-18","conditions":"HPV 16+ Recurrent or Metastatic Cancer","enrollment":24},{"nctId":"NCT04195633","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-25","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT05470491","phase":"PHASE1, PHASE2","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-26","conditions":"HIV, Hematologic Malignancies","enrollment":265},{"nctId":"NCT06995521","phase":"PHASE2","title":"Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population","status":"NOT_YET_RECRUITING","sponsor":"Sung Won Choi","startDate":"2026-03","conditions":"GVHD","enrollment":55},{"nctId":"NCT06517641","phase":"PHASE2","title":"Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-05-12","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT03465592","phase":"PHASE1, PHASE2","title":"Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-05-01","conditions":"Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood","enrollment":39},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT04959175","phase":"PHASE1, PHASE2","title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-23","conditions":"Hematologic Neoplasms","enrollment":320},{"nctId":"NCT04370301","phase":"PHASE2","title":"Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-02-09","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":20},{"nctId":"NCT02171104","phase":"PHASE2","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-10","conditions":"Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome","enrollment":149},{"nctId":"NCT05757310","phase":"PHASE1","title":"A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-11-15","conditions":"Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia","enrollment":6},{"nctId":"NCT03626285","phase":"","title":"Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders","status":"AVAILABLE","sponsor":"OHSU Knight Cancer Institute","startDate":"","conditions":"Benign Neoplasm, Bone Marrow Transplantation Recipient, Hematopoietic Cell Transplantation Recipient","enrollment":""},{"nctId":"NCT04745221","phase":"NA","title":"Efficacy and Safety of Auto-FMT in Preventing aGVHD","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-03-01","conditions":"Graft Versus Host Disease, Acute","enrollment":100},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT07249476","phase":"","title":"Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-02-01","conditions":"Leukaemia (Acute Myeloid), Leukaemia (Acute Lymphoblastic), Myelodysplastic Syndrome","enrollment":55},{"nctId":"NCT02623439","phase":"PHASE2","title":"A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2012-09-21","conditions":"Hematologic Malignancies","enrollment":10},{"nctId":"NCT02996773","phase":"PHASE1","title":"Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2016-11-29","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT02828592","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2016-09-09","conditions":"Severe Aplastic Anemia","enrollment":20},{"nctId":"NCT05236764","phase":"NA","title":"Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2023-12-06","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes","enrollment":3},{"nctId":"NCT03856216","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-28","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm","enrollment":15},{"nctId":"NCT03240731","phase":"PHASE2","title":"HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2017-08-10","conditions":"Sickle Cell Disease","enrollment":25},{"nctId":"NCT01966367","phase":"PHASE1, PHASE2","title":"CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-03","conditions":"Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia","enrollment":37},{"nctId":"NCT03653338","phase":"PHASE1, PHASE2","title":"T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-08-02","conditions":"Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia","enrollment":5},{"nctId":"NCT03047746","phase":"NA","title":"Unrelated And Partially Matched Related Donor PSCT w/ T Cell Receptor (TCR) αβ Depletion for Patients With BMF","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2017-02-01","conditions":"Acquired Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Inherited Bone Marrow Failure Syndromes","enrollment":50},{"nctId":"NCT02446964","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2015-06-25","conditions":"Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome","enrollment":31},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT05473910","phase":"PHASE1","title":"A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation","status":"RECRUITING","sponsor":"TScan Therapeutics, Inc.","startDate":"2022-11-01","conditions":"AML, Myelodysplastic Syndromes, ALL, Adult","enrollment":75},{"nctId":"NCT01350232","phase":"NA","title":"Treatment of Sickle Cell Anemia With Stem Cell Transplant","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-09","conditions":"Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia","enrollment":2},{"nctId":"NCT01350245","phase":"PHASE2","title":"Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia","enrollment":28},{"nctId":"NCT00429143","phase":"PHASE1, PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-01","conditions":"Hematologic Malignancies","enrollment":27},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT03755414","phase":"PHASE1","title":"Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-09-04","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes","enrollment":55},{"nctId":"NCT02100891","phase":"PHASE2","title":"Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors","status":"TERMINATED","sponsor":"Monica Thakar","startDate":"2013-03-20","conditions":"Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma","enrollment":15},{"nctId":"NCT02880293","phase":"NA","title":"Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-08-23","conditions":"Hematologic Malignancy","enrollment":44},{"nctId":"NCT01019876","phase":"PHASE2, PHASE3","title":"Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09","conditions":"Bone Marrow Failure, Osteopetrosis, Fanconi Anemia","enrollment":38},{"nctId":"NCT03088709","phase":"PHASE2","title":"Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide","status":"TERMINATED","sponsor":"Loyola University","startDate":"2017-01-18","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT02065596","phase":"PHASE1","title":"Hematopoietic Stem Cell Transplant for Sickle Cell Disease","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-10-19","conditions":"Sickle Cell Disease, Sickle Cell Anemia, SCD","enrollment":4},{"nctId":"NCT01927731","phase":"PHASE2","title":"Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-14","conditions":"Bone Marrow Transplantation Recipient, Cord Blood Transplant Recipient, Hematopoietic Cell Transplantation Recipient","enrollment":48},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT01904136","phase":"PHASE1, PHASE2","title":"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-04-22","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations","enrollment":54},{"nctId":"NCT05126849","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-01-06","conditions":"Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":31},{"nctId":"NCT04478474","phase":"","title":"Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2020-09-15","conditions":"Cytomegalovirus Infections","enrollment":100},{"nctId":"NCT04166929","phase":"PHASE2","title":"Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-01-15","conditions":"Acute Myeloid Leukemia, Myelodysplasia","enrollment":6},{"nctId":"NCT05392894","phase":"PHASE3","title":"RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2023-02-23","conditions":"Sickle Cell Disease","enrollment":120},{"nctId":"NCT02224872","phase":"PHASE2","title":"Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08","conditions":"Severe Aplastic Anemia, Bone Marrow Failure Syndromes","enrollment":18},{"nctId":"NCT00849147","phase":"PHASE2","title":"Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2008-10","conditions":"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma","enrollment":55},{"nctId":"NCT02918292","phase":"PHASE2","title":"Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-07-03","conditions":"Severe Aplastic Anemia","enrollment":32},{"nctId":"NCT05528354","phase":"EARLY_PHASE1","title":"Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2022-06-02","conditions":"Hematopoietic Stem Cell Transplantation, TP53","enrollment":58},{"nctId":"NCT02833805","phase":"PHASE2","title":"NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09","conditions":"Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure","enrollment":21},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT02999854","phase":"PHASE3","title":"Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer","status":"TERMINATED","sponsor":"Kiadis Pharma","startDate":"2017-11-29","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome","enrollment":63},{"nctId":"NCT01597778","phase":"PHASE3","title":"Double Cord Versus Haploidentical (BMT CTN 1101)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2012-06","conditions":"Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma","enrollment":368},{"nctId":"NCT02120157","phase":"PHASE2","title":"Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-07-02","conditions":"Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival","enrollment":35},{"nctId":"NCT05126186","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-01","conditions":"Hematologic Diseases, Graft Failure, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":35},{"nctId":"NCT02425787","phase":"","title":"Bereaved Parent Study","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-03-01","conditions":"Bereavement","enrollment":66},{"nctId":"NCT04622956","phase":"PHASE1, PHASE2","title":"GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-07","conditions":"Graft Vs Host Disease, Hematopoietic Neoplasm","enrollment":47},{"nctId":"NCT00606723","phase":"PHASE3","title":"Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2010-04","conditions":"Acute Myeloid Leukemia (AML)","enrollment":154},{"nctId":"NCT00358657","phase":"PHASE2","title":"Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-05-24","conditions":"Immunodeficiency Syndrome, Severe Aplastic Anemia, Genetic Disorder","enrollment":14},{"nctId":"NCT01607580","phase":"NA","title":"Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease(GVHD)","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2012-06","conditions":"Leukemia","enrollment":145},{"nctId":"NCT03236220","phase":"PHASE2","title":"Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2017-08-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":35},{"nctId":"NCT03955601","phase":"PHASE2","title":"A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:","status":"UNKNOWN","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2018-07-12","conditions":"Aplastic Anemia Idiopathic","enrollment":30},{"nctId":"NCT00566696","phase":"PHASE2","title":"Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-14","conditions":"Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML)","enrollment":73},{"nctId":"NCT00857389","phase":"PHASE2","title":"Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-02","conditions":"Stem Cell Transplantation, Leukemia, Lymphoma","enrollment":60},{"nctId":"NCT01010217","phase":"PHASE2","title":"Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-11-05","conditions":"Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies","enrollment":176},{"nctId":"NCT01749293","phase":"PHASE2","title":"Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2012-08-30","conditions":"Hematologic Malignancies","enrollment":3},{"nctId":"NCT00789776","phase":"PHASE1, PHASE2","title":"Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-10-13","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma","enrollment":41},{"nctId":"NCT00453388","phase":"PHASE2","title":"Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-02","conditions":"Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia","enrollment":6},{"nctId":"NCT00040417","phase":"PHASE2","title":"Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2000-08","conditions":"Sickle Cell Anemia, Hemoglobinopathy, Thalassemia","enrollment":15},{"nctId":"NCT02145039","phase":"NA","title":"Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-10","conditions":"Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia","enrollment":2},{"nctId":"NCT00185692","phase":"PHASE2","title":"Allogeneic Transplantation From Related Haploidentical Donors","status":"COMPLETED","sponsor":"Stanford University","startDate":"2000-08","conditions":"Blood Cancer, Leukemia, Graft Versus Host Disease","enrollment":16},{"nctId":"NCT02080195","phase":"PHASE1, PHASE2","title":"Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09-13","conditions":"Lupus Erythematosus, Graft-versus-host Disease","enrollment":1},{"nctId":"NCT02013375","phase":"PHASE2","title":"SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD","status":"TERMINATED","sponsor":"Damiano Rondelli, MD","startDate":"2014-04-10","conditions":"Sickle Cell Disease","enrollment":2},{"nctId":"NCT01008462","phase":"PHASE2","title":"Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-03-18","conditions":"B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p","enrollment":16},{"nctId":"NCT02042690","phase":"PHASE3","title":"Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Peking University","startDate":"2014-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":131},{"nctId":"NCT00796562","phase":"PHASE2","title":"Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-12","conditions":"MDS, Leukemias, Lymphomas","enrollment":107},{"nctId":"NCT03758911","phase":"","title":"Perspectives on Bone Marrow Donors Who Donate for Their Parent","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-12-06","conditions":"Bone Marrow Transplant","enrollment":16},{"nctId":"NCT03298399","phase":"PHASE1","title":"Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2017-12-21","conditions":"Sickle Cell Disease","enrollment":""},{"nctId":"NCT03655145","phase":"PHASE3","title":"HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-08","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myeloproliferative Syndromes","enrollment":344},{"nctId":"NCT01135329","phase":"PHASE2","title":"Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-08","conditions":"Lymphoma, Leukemia, Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT02702960","phase":"PHASE2","title":"Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03","conditions":"Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT02277639","phase":"PHASE2","title":"Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2011-11","conditions":"Bone Marrow Failure Syndromes, Immunodeficiencies, Immune Dysregulation Syndromes","enrollment":2},{"nctId":"NCT00101140","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission","status":"WITHDRAWN","sponsor":"Eastern Cooperative Oncology Group","startDate":"","conditions":"Adult Acute Erythroid Leukemia, Adult Acute Monoblastic and Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT00049504","phase":"PHASE2","title":"Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2002-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":53},{"nctId":"NCT00005988","phase":"PHASE1","title":"Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2000-02","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":5},{"nctId":"NCT02519114","phase":"PHASE1, PHASE2","title":"Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2015-08","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT01383434","phase":"PHASE2","title":"Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2011-06","conditions":"Severe Aplastic Anemia","enrollment":4},{"nctId":"NCT00526292","phase":"PHASE2","title":"Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-08","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":12},{"nctId":"NCT00731328","phase":"PHASE2","title":"Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2008-04","conditions":"Leukemia, Myelodysplastic Syndromes, Nonmalignant Neoplasm","enrollment":15},{"nctId":"NCT00134004","phase":"PHASE2","title":"Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2004-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Haploidentical Bone Marrow Transplant","genericName":"Haploidentical Bone Marrow Transplant","companyName":"Medical College of Wisconsin","companyId":"medical-college-of-wisconsin","modality":"Biologic","firstApprovalDate":"","aiSummary":"Haploidentical bone marrow transplant replaces a patient's diseased bone marrow with stem cells from a partially matched donor to restore hematopoietic and immune function. Used for Acute leukemia (AML, ALL), Chronic leukemia (CML, CLL), Lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}